MA-BATTERY-VENTURES
15.9.2021 13:02:10 CEST | Business Wire | Press release
Battery Ventures, a global, technology-focused investment firm, promoted software investor Jordan Welu to the role of partner and announced a dozen other internal promotions as it expands the global reach of its venture-capital and private-equity businesses worldwide. Battery is currently investing its 13th family of funds, raised in early 2020 and capitalized at a combined $2 billion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005299/en/
Welu, who joined Battery in 2014, is a B2B-tech investor who focuses on growth-stage and buyout investments in areas such as infrastructure software, cybersecurity and financial technology. He is currently involved with Battery portfolio companies Alogent, DomainTools, Forest2Market, Learnosity and Plixer. Previously, he backed Concurrent Real-Time (acquired by Spectris) and Enviance (acquired by Cority).
Prior to Battery, Welu, who is based in Boston, worked in software corporate development and finance at companies including Rogue Wave Software, a former Battery portfolio company, and Webroot. Earlier in his career, he worked in investment banking and equity research. Jordan is a graduate of Georgetown University.
Battery also named two existing team members to the role of principal: Roland Anderson, based in Boston, and Satoshi Harris-Koizumi, based in New York. Both specialize in software investments. Anderson joined Battery in 2014 and Harris-Koizumi in 2012.
There were also six promotions to vice president. These include Danel Dayan and Courtney Chow in Menlo Park; Mike Hoeksema and Viraj Parmar in New York; Lauren Wedell in Boston; and Lior Mallul in Herzliya, Israel. In addition, Battery promoted three team members to associate. These include Maximilian Jessen and Matt Klineman, based in Boston, and Diego Liranzo in New York. Earlier this year, Battery promoted Antonia Heiss, based in London, to associate. Finally, the firm announced it has hired Jenny Kang as the firm’s vice president of talent for venture- and growth-stage companies. Previously, Kang was the head of go-to-market executive recruiting at Sequoia Capital.
“Jordan’s promotion to partner, following his work with Concurrent Real-Time and Enviance, is richly deserved, as are the promotions of all the new principals, vice presidents and associates,” said Jesse Feldman, a Battery general partner who helped make the original investment in Welu’s previous employer Rogue Wave Software. “More broadly, the moves highlight Battery’s longtime preference for promoting talent from within the firm as we seek out the most promising technology investments regardless of stage, sector or geography. We’re also very excited to add Jenny Kang to our team as we continue to offer more value-added services, including recruiting and talent assistance, to our portfolio companies.”
In the last 12 months, Battery has seen seven of its portfolio companies—Affirm, Coinbase, Confluent, JFrog, Olo, Sprinklr and Sumo Logic—stage initial public offerings. Since its founding in 1983 through June 30 of this year, Battery has funded 468 companies, not including seed investments, and realized 185 M&A events and 69 IPOs in total.
About Battery Ventures
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Herzliya, Israel; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005299/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
